HomeDiscussions$ANGO Q4 '26 Earnings Results & Recap
AngioDynamics projects fiscal 2027 net sales of $336.0M-$341.0M, with Med Tech sales growth of 12%-15% and Med Device sales flat. Gross margin is anticipated at 54%-55% and adjusted EBITDA at $13.0M-$16.0M.
Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
$ANGO Q4 '26 Earnings Results & Recap
AngioDynamics projects fiscal 2027 net sales of $336.0M-$341.0M, with Med Tech sales growth of 12%-15% and Med Device sales flat. Gross margin is anticipated at 54%-55% and adjusted EBITDA at $13.0M-$16.0M.